Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Recs

0
Player Avatar NorthonCharles (< 20) Submitted: 10/16/2010 12:35:08 PM : Outperform Start Price: $17.13 SGEN Score: +7.89

New product approval.

Report this Post Reply

Featured Broker Partners


Advertisement